Explore our recent stories to see what drives us
Grünenthal’s two latest corporate reports are now available
At Grünenthal, we are deeply committed to open communication with all stakeholders. Our two corporate reports are key elements of that approach. They provide clear and comprehensive information from across our business – including details about how our teams are supporting progress towards our company’s vision of a World Free of Pain.
The Grünenthal Report offers facts and figures on our company’s strategic objectives and financial performance, as well as highlighting projects and key business developments.
- Grünenthal's people have transformed our company over the last few years, uniquely positioning us to meet the increased demand for better pain treatments.
- Our medicines today help more patients than ever before as we are growing our footprint in key pharmaceutical markets, especially in the United States.
- We advanced key R&D projects, creating one of the strongest pain-focused pipelines in the industry.
- We ensured uninterrupted supply of medicines to patients in over 100 countries.
- Through strategic acquisitions, we expanded our portfolio of established medicines.
Read more in the Grünenthal Report 2023/2024.
The Responsibility Report shares updates on our Environmental, Social and Governance ambitions, and transparently communicates our progress.
- We reduced our total energy consumption by 7.7% vs. 2022 following investments in energy efficiency and transition to increased renewable energy.
- Grünenthal reduced the direct emissions from its activities by 13.3% vs 2022.
- Our employees spent 3,000 hours volunteering in our local communities.
Read more in the Grünenthal Responsibility Report 2023.
